Revelation Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting a net loss of $3,315,513 for the three months ended September 30, 2026.

Key Highlights

  • Net loss of $3,315,513 for the three months ended September 30, 2026, compared to a net loss of $1,907,176 in the same period of 2025, according to the filing.
  • Total operating expenses reached $3,383,576 in Q3 2026, up from $1,943,011 in Q3 2025, driven by research and development expenses of $1,512,898 and general and administrative expenses of $1,870,678.
  • Cash and cash equivalents of $9,121,630 as of September 30, 2026, down from $10,700,331 at December 31, 2025.
  • Accumulated deficit of $59,067,235 as of September 30, 2026, compared to $49,419,287 at December 31, 2025.
  • 683,442 shares of common stock outstanding as of November 2, 2026, up from 226,330 at December 31, 2025.
  • Class I Warrant Inducement exercises in Q1 2026 generated net proceeds of $6,666,012, the filing disclosed.
  • Nine-month net loss of $9,647,948 for the period ended September 30, 2026, versus $6,402,643 for the same period in 2025.

Revelation Biosciences Q3 2026 Financial Results: Wider Losses, Declining Cash

According to the filing, Revelation Biosciences (NASDAQ:REVB) reported total operating expenses of $3,383,576 for the three months ended September 30, 2026, compared to $1,943,011 in the prior-year quarter. Research and development expenses increased to $1,512,898 from $922,857, while general and administrative expenses rose to $1,870,678 from $1,020,154 in the same period of 2025. The company reported other income of $68,063 for Q3 2026, partially offsetting the operating loss.

The filing disclosed that cash and cash equivalents stood at $9,121,630 as of September 30, 2026, a decrease of $1,578,701 from the $10,700,331 balance at December 31, 2025. Net cash used in operating activities for the nine months ended September 30, 2026 was $8,133,206. Financing activities provided $6,666,012 in net proceeds, all from Class I Warrant Inducement exercises. Total assets as of September 30, 2026 were reported at $10,022,097, against total liabilities of $2,788,395, resulting in total stockholders' equity of $7,233,702.

The company disclosed stock-based compensation expense of $1,354,643 for the nine months ended September 30, 2026. The share count increased substantially over the nine-month period: 305,180 shares were issued through Class I Warrant Inducement exercises in Q1 2026, contributing $6,665,707 to additional paid-in capital. As of September 30, 2026, additional paid-in capital totaled $66,300,254. The net loss per share, basic and diluted, was $(5.92) for Q3 2026 on weighted-average shares of 559,596.

What Was Disclosed

Revelation Biosciences filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $3,315,513, a nine-month net loss of $9,647,948, cash of $9,121,630, and total stockholders' equity of $7,233,702 as of the period end.